ANXA7 and prostate carcinoma: It is intriguing to suggest that the effects of wt-ANXA7 versus those of the dominant-negative DN-ANXA7J on the endogenous prostate-specific tumor suppressor 15-LOX2 in prostate cancer cells [16] could have incorporated PLD-mediated polyisoprenyl–phosphate signaling, which is a switch regulated by lipoxins and leukotrienes, the arachidonate autocoids with opposing responses in immunity and apoptosis [71].